The Regenerative Medicine in Pharma market size was valued at US$29.4 billion in 2021 and is expected to grow at a compound annual growth rate (CAGR) of 11.1% during 2022-2027. The Regenerative Medicine in Pharma market report provides an executive-level overview of the regenerative medicine market worldwide today, with detailed forecasts of key indicators up to 2027.
This market intelligence report offers a thorough, forward-looking analysis of the Regenerative Medicine in Pharma market, and key product and platform stack in a concise format to help executives build proactive and profitable growth strategies.
The regenerative medicine in pharma market size was valued at US$29.1 billion in 2021 and is expected to grow at a compound annual growth rate (CAGR) of 11.1% during the forecast period (2022-2027). The market is driven by the growing prevalence of chronic diseases, genetic disorders, and cancer and technological advancements in stem-cell therapies.
This market intelligence report offers a thorough, forward-looking analysis of the Regenerative Medicine in Pharma market, and key product and platform stack in a concise format to help executives build proactive and profitable growth strategies.
The regenerative medicine in pharma market size was valued at US$29.1 billion in 2021 and is expected to grow at a compound annual growth rate (CAGR) of 11.1% during the forecast period (2022-2027). The market is driven by the growing prevalence of chronic diseases, genetic disorders, and cancer and technological advancements in stem-cell therapies.
Scope
- Overview of regenerative medicine in pharma market including industry trends, funding & deals, pipeline analysis, regulatory details, and product & company profile
- Regenerative medicine in pharma market outlook: analysis as well as historical figures and forecasts of revenue opportunities from the product, technology, application, and geographic segments.
- Regenerative medicine in pharma market outlook: analysis as well as forecasts of revenue opportunities from the drug class segments.
- Regenerative medicine in pharma market outlook: analysis as well as forecasts of revenue opportunities from the route of administration segment.
- The competitive landscape: an examination of the positioning of leading players in regenerative medicine in pharma market.
Reasons to Buy
- This market intelligence report offers a thorough, forward-looking analysis of the Regenerative Medicine in Pharma market and key opportunities in a concise format to help executives build proactive and profitable growth strategies.
- Accompanying the publisher's Forecast products, the report examines the assumptions and drivers behind ongoing and upcoming trends in regenerative medicine in pharma markets.
- The report also highlights key product, therapeutic area segments.
- With different charts and tables, the report is designed for an executive-level audience, boasting presentation quality.
- The report provides an easily digestible market assessment for decision-makers built around in-depth information gathered from market players, which enables executives to quickly get up to speed with the current and emerging trends in regenerative medicine in pharma market.
Table of Contents
CHAPTER 01 Executive Summary
CHAPTER 02 Market Landscape
CHAPTER 03 Regenerative Medicine in Pharma Value Chain
CHAPTER 04 Regulatory and Market Access
CHAPTER 05 Marketed Products
CHAPTER 06 Regenerative Medicine Pipeline Products in the 8MM
CHAPTER 07 Regenerative Medicine in Pharma Industry Analysis
CHAPTER 08 Global Regenerative Medicine in Pharma Revenue Opportunity
CHAPTER 09 Regenerative Medicine in Pharma Product Outlook
CHAPTER 010 Regenerative Medicine in Pharma Therapeutic Area Outlook
CHAPTER 011 Regenerative Medicine in Pharma Regional Outlook
CHAPTER 012 Trends, Drivers, and Challenges
CHAPTER 013 Regenerative Medicine in Pharma Market Vendor Snapshot
CHAPTER 014 Appendix
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Novartis
- Gilead
- Amgen
- BRISTOL-MYERS SQUIBB COMPANY
- Bluebird bio
- Johnson & Johnson
- Biomarin
- PTC Therapeutics
- Orchard Therapeutics